Cancer Family
Malignant Head and Neck Neoplasm
CI-CAN-00000236Explore in graph →
1,432 active trials17 approved drugs142 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000236Explore in graph →
Clinical trials
5,449 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (629)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03427411 | M7824 in Subjects With HPV Associated Malignancies | completed | Phase 2 | 57 | National Cancer Institute (NCI)NIH | 1 | Mar 28, 2023 | clinicaltrials |
| NCT04208334 | The Effect of Curcumin for Treatment of Cancer Anorexia-Cachexia Syndrome in Patients With Stage III-IV of Head and Neck Cancer(CurChexia) | completed | Phase 2 | 20 | Phramongkutklao College of Medicine and HospitalOTHER | 1 | Mar 28, 2023 |
| clinicaltrials |
| NCT02990468 | A Trial of Concurrent Radiation Therapy, Cisplatin, and BMX-001 in Locally Advanced Head and Neck Cancer(BMX-HN) | completed | Phase 1 / Phase 2 | 29 | BioMimetix JV, LLCINDUSTRY | 1 | Mar 15, 2023 | clinicaltrials |
| NCT02126969 | A Study of Chemo +/- Low-dose Radiation as Induction Therapy in SCCHN | completed | Phase 2 | 45 | Susanne ArnoldOTHER | 1 | Mar 13, 2023 | clinicaltrials |
| NCT00258310 | Ph II Long Term/Low Dose Xeloda in Head and Neck Squamous Cell Carcinoma After Surgery, Radiation & or Chemo | completed | Phase 2 | 35 | Barbara Ann Karmanos Cancer InstituteOTHER | 1 | Mar 10, 2023 | clinicaltrials |
| NCT00702481 | Study of Nimotuzumab and Cisplatin/Radiotherapy for Locally Advanced Head and Neck Squamous Cell Cancer | completed | Phase 2 | 32 | National Cancer Centre, SingaporeOTHER | 1 | Feb 28, 2023 | clinicaltrials |
| NCT02707588 | Tolerance and Efficacy of Pembrolizumab or Cetuximab Combined With RT in Patients With Locally Advanced HNSCC(PembroRad) | completed | Phase 2 | 133 | Groupe Oncologie Radiotherapie Tete et CouOTHER | 1 | Feb 28, 2023 | clinicaltrials |
| NCT01173172 | Boron Neutron Capture Therapy (BNCT) for Locally Recurrent Head and Neck Cancer(BNCT) | completed | Phase 1 / Phase 2 | 17 | Taipei Veterans General Hospital, TaiwanOTHER_GOV | 1 | Feb 22, 2023 | clinicaltrials |
| NCT03999684 | A Trial of All-trans Retinoic Acid (ATRA) in Advanced Adenoid Cystic Carcinoma | completed | Phase 2 | 18 | Dana-Farber Cancer InstituteOTHER | 1 | Jan 23, 2023 | clinicaltrials |
| NCT04350190 | Apatinib Combined With PD-1 in the Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma | completed | Phase 2 | 25 | Wei JiangOTHER | 1 | Jan 13, 2023 | clinicaltrials |
| NCT01882816 | Intensity-Modulated Radiation Therapy (IMRT) in the Treatment of Non-Anaplastic Non-Medullary Thyroid Cancer | completed | Phase 2 | 27 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Dec 29, 2022 | clinicaltrials |
| NCT02643303 | A Study of Tremelimumab and IV Durvalumab Plus Poly-ICLC in Subjects With Biopsy-accessible Cancers | completed | Phase 1 / Phase 2 | 58 | Ludwig Institute for Cancer ResearchOTHER | 1 | Dec 2, 2022 | clinicaltrials |
| NCT01874860 | Skin Rash Study Before Chemotherapy in Colorectal & Head and Neck Cancer Patients | completed | Phase 2 | 24 | University of LouisvilleOTHER | 1 | Dec 1, 2022 | clinicaltrials |
| NCT03620123 | A Randomized Phase II Study on the Optimization of Immunotherapy in Squamous Carcinoma of the Head and Neck(OPTIM) | completed | Phase 2 | 54 | AIO-Studien-gGmbHOTHER | 1 | Nov 18, 2022 | clinicaltrials |
| NCT03405142 | Panitumumab-IRDye800 Compared to Sentinel Node Biopsy and (Selective) Neck Dissection in Identifying Metastatic Lymph Nodes in Patients With Head&Neck Cancer | completed | Phase 2 | 3 | Eben RosenthalOTHER | 1 | Nov 10, 2022 | clinicaltrials |
| NCT01088802 | Treatment De-Intensification for Squamous Cell Carcinoma of the Oropharynx | completed | Phase 2 | 60 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Nov 8, 2022 | clinicaltrials |
| NCT02965001 | Phase II Trial: uPAR-PET/CT for Prognostication in Head- and Neck Cancer | completed | Phase 2 | 57 | Rigshospitalet, DenmarkOTHER | 1 | Nov 3, 2022 | clinicaltrials |
| NCT03502148 | Safety and Efficacy Study of PRV111 in Subjects With Oral Squamous Cell Carcinoma(PRV111) | completed | Phase 1 / Phase 2 | 10 | Privo TechnologiesINDUSTRY | 1 | Oct 21, 2022 | clinicaltrials |
| NCT02704169 | Quantitative Endoscopy of H&N | completed | Phase 2 | 15 | University Health Network, TorontoOTHER | 1 | Oct 19, 2022 | clinicaltrials |
| NCT03087019 | Pembrolizumab With or Without Radiation in Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma | completed | Phase 2 | 21 | Dana-Farber Cancer InstituteOTHER | 1 | Oct 14, 2022 | clinicaltrials |
| NCT00446446 | PRISM (Panitumumab Regimen In Second-line Monotherapy of Head and Neck Cancer) | completed | Phase 2 | 52 | AmgenINDUSTRY | 0 | Oct 5, 2022 | clinicaltrials |
| NCT01458392 | Study of Dalantercept in Patients With Squamous Cell Carcinoma of the Head and Neck | completed | Phase 2 | 46 | Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USAINDUSTRY | 1 | Oct 5, 2022 | clinicaltrials |
| NCT02002182 | ADXS 11-001 Vaccination Prior to Robotic Surgery, HPV-Positive Oropharyngeal Cancer | completed | Phase 2 | 15 | Andrew SikoraOTHER | 1 | Sep 22, 2022 | clinicaltrials |
| NCT01592721 | Radiation and Cetuximab Plus Intratumoral EGFR Antisense DNA in Locally Advanced Head and Neck Squamous Cell Carcinoma | completed | Phase 1 / Phase 2 | 6 | The University of Texas Health Science Center at San AntonioOTHER | 1 | Sep 21, 2022 | clinicaltrials |
| NCT03162224 | Safety and Efficacy of MEDI0457 and Durvalumab in Participants With Human Papilloma Virus (HPV) Associated Recurrent/Metastatic Head and Neck Cancer | completed | Phase 1 / Phase 2 | 35 | MedImmune LLCINDUSTRY | 1 | Aug 25, 2022 | clinicaltrials |
| NCT02268695 | Platinum-Cetuximab Combined With Docetaxel or With 5FU in Patients With Recurrent/Metastatic HNSCC(TPExtreme) | completed | Phase 2 | 541 | Groupe Oncologie Radiotherapie Tete et CouOTHER | 3 | Aug 23, 2022 | clinicaltrials |
| NCT01864772 | Phase II Trial of Carboplatin, 5-FU and Cetuximab in Elderly Fit (no Frailty) Patients With Recurrent/Metastatic HNSCC(ELANFIT) | completed | Phase 2 | 85 | Groupe Oncologie Radiotherapie Tete et CouOTHER | 1 | Aug 19, 2022 | clinicaltrials |
| NCT04529850 | Ph 2 Open Label Study of GC4419 to Reduce SOM Associated With Chemoradiotherapy for Head and Neck Cancer | completed | Phase 2 | 38 | Galera Therapeutics, Inc.INDUSTRY | 6 | Aug 16, 2022 | clinicaltrials |
| NCT01514344 | Intralesional Rituximab for the Treatment of Conjunctival Indolent Lymphoma(IRIS) | completed | Phase 2 | 20 | Andres J. M. FerreriOTHER | 1 | Aug 4, 2022 | clinicaltrials |
| NCT02404441 | Phase I/II Study of PDR001 in Patients With Advanced Malignancies | completed | Phase 1 / Phase 2 | 319 | Novartis PharmaceuticalsINDUSTRY | 14 | Aug 3, 2022 | clinicaltrials |
| NCT01730638 | ImmunoTEP for Patients With Medullary Thyroid Carcinoma.(iTEP-CMT) | completed | Phase 1 / Phase 2 | 25 | Nantes University HospitalOTHER | 1 | Jul 26, 2022 | clinicaltrials |
| NCT01236547 | Intensity-Modulated Radiation Therapy and Paclitaxel With or Without Pazopanib Hydrochloride in Treating Patients With Anaplastic Thyroid Cancer | completed | Phase 2 | 123 | National Cancer Institute (NCI)NIH | 1 | Jul 19, 2022 | clinicaltrials |
| NCT03057613 | The Addition of Pembrolizumab to Postoperative Radiotherapy in Cutaneous Squamous Cell Cancer of the Head and Neck | completed | Phase 2 | 18 | Case Comprehensive Cancer CenterOTHER | 1 | Jun 30, 2022 | clinicaltrials |
| NCT02255097 | Study of MK-3475 (Pembrolizumab) in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma After Treatment With Platinum-based and Cetuximab Therapy (MK-3475-055/KEYNOTE-055) | completed | Phase 2 | 172 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Jun 28, 2022 | clinicaltrials |
| NCT01884259 | Induction Chemotherapy With TP+5-FU or TP+Cetuximab Followed by Radioimmuptherapy for Locally Advanced or Not Resectable SCCHNN(HNO-2) | completed | Phase 2 | 100 | Arbeitsgemeinschaft medikamentoese TumortherapieOTHER | 1 | May 26, 2022 | clinicaltrials |
| NCT04834206 | Nedaplatin in Treatment for Nasopharyngeal Carcinoma | completed | Phase 2 | 32 | Affiliated Cancer Hospital & Institute of Guangzhou Medical UniversityOTHER | 1 | May 10, 2022 | clinicaltrials |
| NCT03633110 | Safety, Tolerability, Immunogenicity, and Antitumor Activity of GEN-009 Adjuvanted Vaccine | completed | Phase 1 / Phase 2 | 24 | Genocea Biosciences, Inc.INDUSTRY | 1 | Apr 19, 2022 | clinicaltrials |
| NCT00971867 | Rollover Study of Weekly Paclitaxel (BMS-181339) in Patients With Head and Neck Cancer | completed | Phase 2 | 11 | Bristol-Myers SquibbINDUSTRY | 1 | Apr 8, 2022 | clinicaltrials |
| NCT04508816 | Anti-EGFR Therapy Plus IMRT Concurrent Chemoradiotherapy in Locally Advanced NPC Resistant to Induction Chemotherapy | completed | Phase 2 | 45 | Fudan UniversityOTHER | 1 | Apr 4, 2022 | clinicaltrials |
| NCT03292250 | Korean Cancer Study Group: Translational bIomarker Driven UMbrella Project for Head and Neck (TRIUMPH), Esophageal Squamous Cell Carcinoma- Part 1 (HNSCC)] | completed | Phase 2 | 180 | Seoul National University HospitalOTHER | 1 | Mar 29, 2022 | clinicaltrials |
| NCT03067610 | Involved Field Elective Volume De-Intensification Radiation Therapy for Head and Neck Cancer(INFIELD) | completed | Phase 2 | 72 | University of Texas Southwestern Medical CenterOTHER | 1 | Mar 17, 2022 | clinicaltrials |
| NCT03330249 | Comparison of Two Concomitant Administration of RT With Cisplatin in Standard Infusion or Fractional Infusion(CisFRad) | completed | Phase 2 | 124 | Groupe Oncologie Radiotherapie Tete et CouOTHER | 1 | Mar 11, 2022 | clinicaltrials |
| NCT02684253 | Screening Trial of Nivolumab With Image Guided, Stereotactic Body Radiotherapy (SBRT) Versus Nivolumab Alone in Patients With Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) | completed | Phase 2 | 65 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Mar 10, 2022 | clinicaltrials |
| NCT02873819 | Safety and Efficacy Study of GL-0817 (With Cyclophosphamide) for the Prevention of Recurrence of Squamous Cell Carcinoma of the Oral Cavity | completed | Phase 2 | 80 | Gliknik Inc.INDUSTRY | 7 | Mar 8, 2022 | clinicaltrials |
| NCT02562599 | Chemoradiotherapy for Patients With Locally Advanced Nasopharyngeal Carcinoma Using Raltitrexed-Cisplatin | completed | Phase 2 | 60 | Hubei Cancer HospitalOTHER | 1 | Feb 22, 2022 | clinicaltrials |
| NCT01104922 | Re-irradiation With Fractionated Stereotactic Radiosurgery Plus Cetuximab in Patients With Recurrent Squamous Cell Carcinoma of the Head and Neck | completed | Phase 2 | 48 | David A. Clump, MD, PhDOTHER | 1 | Feb 14, 2022 | clinicaltrials |
| NCT02178722 | Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers | completed | Phase 1 / Phase 2 | 444 | Incyte CorporationINDUSTRY | 1 | Feb 14, 2022 | clinicaltrials |
| NCT02237924 | Endostar Combined With Intensity-modulated Radiotherapy Compare With Chemoradiation for Nasopharyngeal Carcinoma | completed | Phase 2 | 120 | First Affiliated Hospital of Guangxi Medical UniversityOTHER | 1 | Feb 14, 2022 | clinicaltrials |
| NCT00099021 | Pioglitazone Hydrochloride in Preventing Head and Neck Cancer in Patients With Oral Leukoplakia | completed | Phase 2 | 21 | National Cancer Institute (NCI)NIH | 1 | Feb 11, 2022 | clinicaltrials |
Data updated 23 days agoSource updated Mar 28, 2023source: clinicaltrials